Federal Circuit Denies Rehearing In Dispute Over Biologics, Patents
(October 19, 2015, 10:34 AM EDT) -- WASHINGTON, D.C. — Competing motions for en banc rehearing of a July 2015 ruling by the Federal Circuit U.S. Court of Appeals in a dispute over the Biologics Price Competition and Innovation Act (BPCIA) were denied by the Federal Circuit on Oct. 16 (Amgen Inc. et al. v. Sandoz Inc. et al., No. 15-1499, Fed. Cir.).
(Order available. Document #16-151102-003R.)
According to the Federal Circuit “the petitions for rehearing were first referred to the panel that heard the appeal, and thereafter, to the circuit judges who...